#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Bariatric surgery volumes fell 39%
Epic Cosmos data show US bariatric surgery peaked in Q4 2022 and fell 39% by Q4 2025. Access to GLP-1 agonists before surgery splits sharply by insurance.
GLP-1 RAs in aging people with HIV
A 2026 review finds semaglutide reduces weight, improves cardiometabolic markers, and may slow epigenetic aging in people with HIV, but key safety gaps remain.
Semaglutide, NAION, and a retracted study
A 2025 paper in Retina on semaglutide and optic nerve risk has been retracted without a stated reason, complicating an already contested safety debate.
T2D and obesity: why treatment falls short
A July 2026 expert review finds clinicians undertreat obesity in type 2 diabetes, leaving a key driver of glycaemic failure and cardiovascular risk unaddressed.
Tirzepatide and kidney function in obesity
A 36-person real-world study found three months of tirzepatide improved eGFR in adults with obesity, with BMI change explaining about 19% of the kidney benefit.
Tirzepatide and platelet volume in obesity
A 60-person retrospective study found tirzepatide reduced mean platelet volume 0.94 fL with a 3.92 BMI-unit drop. What the data shows and where it falls short.
Semaglutide in Pakistan: real-world data
A 30-week Pakistan study reports HbA1c reductions of 1.86 points and 7.84 kg mean weight loss with semaglutide in routine outpatient care.
Crunchometer: open-source feeding analysis
An open-source acoustic device for mice detects semaglutide appetite suppression and maps meal-tracking neurons in the lateral hypothalamus.
GLP-1 vs oral agents: insulin stop in T2D
A 2026 Annals study found GLP-1 agonists did not raise insulin discontinuation rates above SGLT-2 or DPP-4 inhibitors in 8,869 veterans with type 2 diabetes.
GLP-1 cancer risk vs bariatric surgery
A July 2026 study found GLP-1 receptor agonists were tied to lower colorectal and pancreatic cancer rates than bariatric surgery, not higher.
CRAVE study: GLP-1, food cravings, and diet
The CRAVE study tracked 28 adults on GLP-1 agonists for 24 weeks. Weight fell, diet quality did not improve, and micronutrient intake dropped.
The obesity drug pipeline in 2026
A 2026 JCEM review maps next-generation obesity drugs, from approved dual agonists to triple agonists like retatrutide still in Phase 3.